Answers are grounded in this paper and cite their sources.
The increasing demand for efficient and sustainable CO 2 capture technologies has driven the development of new ionic liquids (ILs) as potential alternatives to established sorbents. However, before large-scale industrial adoption, a comprehensive understanding of the toxicological profiles of these new ILs is essential to ensure human and environmental safety. Thus, in this study, we conducted a toxicological screening of nine imidazolium-based ILs (five previously reported, IL-1–IL-5, and four newly synthesized analogs, IL-6–IL-9), focusing on their inhibitory effects on the activity of human cholinesterase enzymes (acetylcholinesterase, AChE, and butyrylcholinesterase, BuChE). Initial screening at 40 µM revealed that, among the nine ILs, only IL 1-Dodecyl-3-methyl-2-(4-hydroxyphenyl) imidazolium iodide (IL-9), the dodecyl-substituted analog, inhibited human erythrocyte AChE (IC 50 = 3.64 µM) and plasma BuChE (IC 50 = 0.87 µM). When compared with compounds edrophonium and sodium dodecyl sulfate (SDS), only edrophonium inhibited AChE activity (IC 50 = 3.03 µM), and neither edrophonium nor SDS inhibited BuChE considerably. Molecular docking simulations suggested that the long alkyl moiety of IL-9 stabilizes its interaction near the catalytic active site (CAS) and peripheral anionic subsite (PAS) of both AChE and BuChE. While shorter-chain ILs demonstrated no inhibitory effect, the cholinesterase inhibition exhibited by IL-9 indicates that elongating the alkyl chain introduces significant neurotoxic risks. Consequently, future designs of imidazolium-based CO 2 sorbents must carefully balance these structural modifications to ensure environmental and occupational safety.
No takes yet. Share an insight, caveat, or question.
Bittencourt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: